Subscribe to our channel! rupt.ly/subscribe
Mandatory Credit: Community of Madrid
A total of 150 volunteers began testing the coronavirus vaccine developed by pharmaceutical company Janssen on Tuesday at Madrid’s La Paz and La Princesa hospitals.
The volunteers are divided into 10 different vaccination groups, including one that will receive a placebo. The remaining nine will be vaccinated with low, medium, or high doses of the Janssen prototype.
This is the second day of vaccinations taking place in Spain, after another group of 40 people received a dose on Monday at the Marques de Valdecilla Hospital in Santander as part of the clinical trials of the vaccine.
Spain has recorded 603,167 cases of COVID-19 and 30,004 deaths related to the disease, according to the Ministry of Health.
*SOUNDBITES*
SOT, Dolores Ochoa, Head of Research at Hospital de La Princesa (Spanish): “Today what we are going to do is to perform the first vaccinations, and we are telling the procedures they have to carry out once they have been vaccinated to the volunteers.”
SOT, Alberto Borobia, Coordinator of Clinical Trial Unit at La Paz Hospital (Spanish): “They are given a diary, in which they will write down their temperature daily, which they have to take, and all the symptoms and signs they may have, from pain or redness at the place of the puncture, or that they have a fever or any other symptom.”
SOT, Francisco Abad, Head of Pharmacology at Hospital de La Princesa (Spanish): “There are three levels of doses, some subjects will receive a low dose, others a medium dose and others a high dose, there will be a group that will receive a placebo, and then from these groups, some will have the vaccination repeated after one month, others after two months and others after three months. In this way, we are going to evaluate which is the guideline and the most appropriate dose to achieve a good immune response.”
SOT, Francisco Abad, Head of Pharmacology at Hospital de La Princesa (Spanish): “75 volunteers will be included in our centre, 25 of whom are over 65 years old, because it is a group of special risk and usually has a slightly altered immune response, and the rest are 50 volunteers from 18 to 55 years old. All of them are healthy subjects who participate voluntarily because of their interest in contributing to the research of this new vaccine.”
SOT, Francisco Abad, Head of Pharmacology at Hospital de La Princesa (Spanish): “The study is done in three countries, Spain, the Netherlands and Germany, there are 550 volunteers in the three countries, and in Spain, there will be 190. 40 are in Marques de Valdecilla in Santander and 150 in Madrid.”
Video ID: 20200915-036
Video on Demand:
Contact: cd@ruptly.tv
Twitter:
Facebook:
